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A B S T R A C T
Vitamin D3 as a neuroactive steroid hormone plays an important role in the nervous system. Recent clinical and
experimental studies have shown an association between vitamin D-related disorders and epilepsy. Therefore,
this study was designed to examine the eﬀects of chronic administration of vitamin D3 on pentylenetetrazole
(PTZ)-induced seizure in mice.
This interventional study was conducted on 120 mice in 12 groups. Two control groups acutely and
chronically received a mixture of almond oil and paraﬃn; three groups were acutely given vitamin D3 at doses of
2000, 4000 and 6000 IU/kg; three groups chronically received vitamin D3 with similar doses for two weeks and
two groups chronically and acutely received a sub-eﬀective dose of vitamin D3 and diazepam. Slow intravenous
infusion of PTZ (5mg/mL) was performed at a constant rate (0.3mL/min) via an infusion pump to induce clonic
and tonic seizures.
Acute injection of diﬀerent concentrations of vitamin D3 (2000, 4000 and 6000 IU/kg i.p.) did not sig-
niﬁcantly increase a seizure threshold. However, a seizure threshold in the groups chronically treated with 4000,
and 6000 IU/kg of vitamin D3 was signiﬁcantly higher than that in the control group (P < 0.001). Moreover, a
combination of the sub-eﬀective dose of vitamin D3 (2000 IU/kg) and diazepam (0.1mg/kg) signiﬁcantly in-
creased seizure threshold. Our ﬁndings suggest that administration of vitamin D supplement can be considered
as a potential add-on treatment in seizure and due to the vitamin D deﬁciency results from the long-term use of
most anti-seizure drugs, this supplementation becomes more important.
1. Introduction
The most biologically active form of vitamin D in humans is vitamin
D3 (cholecalciferol), which is a fat-soluble steroid pre-hormone. For
several decades, the role of vitamin D was thought to be conﬁned to
Ca2+ and phosphate homeostasis, and to bone formation and main-
tenance, however, current evidence suggests a wider biological role for
Vitamin D3 in the human brain and nervous system (Garcion et al.,
2002). The roles of Vitamin D have been reported in diﬀerent neuro-
logical disorders such as Alzheimer’s and Parkinson’s disease, multiple
sclerosis schizophrenia and aﬀective disorders (Taghizadeh et al.,
2014). A neurological role of Vitamin D is further supported by the
presence of Vitamin D-speciﬁc receptors and enzymes in neurons and
glial cells throughout the brain, in the spinal cord, and in the peripheral
nervous system (Ghaderi et al., 2017). There is also evidence linking
vitamin D disorders to epilepsy. For the ﬁrst time, anticonvulsant
properties 1,25-dihydroxyvitamin D3 have been reported by Siegel
et al. (1984), who found that the administration of active form of vi-
tamin D3 results in the elevation of hippocampal seizure threshold le-
vels in rats. In addition, in an animal study by Kalueﬀ et al. (2005) have
shown the anticonvulsant eﬀects of 1,25-dihydroxyvitamin D in che-
mically induced seizures in mice (Kalueﬀ et al., 2005). Although vi-
tamin D deﬁciency is known to be highly prevalent among epileptic
patients, only a few studies evaluate the eﬀect of vitamin D on seizure
control. In a pilot study, the serum 25-hydroxy-vitamin D (25(OH)D)
levels were measured and normalized by the administration of vitamin
D3 in 13 patients with pharmacoresistant epilepsy. They found that
seizure numbers signiﬁcantly decreased upon vitamin D3 supple-
mentation and concluded that the normalization of serum vitamin
25(OH)D level has an anticonvulsant eﬀect (Holló et al., 2012). Vitamin
D3 decreases the expression of certain proconvulsant cytokines, such as
IL-1β and TNF-α (Pendo and DeGiorgio, 2016). Vitamin D3 can also
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increase the expression of anticonvulsant growth factors such as nerve
growth factor (Wion et al., 1991). Vitamin D3 may change plasma and
brain calcium concentrations through enhancement of calcium ab-
sorption from the intestine, which may decrease neuronal excitability
and reduce the risk of seizure. It was also suggested that the rapid
anticonvulsant eﬀect of vitamin D3 could be mediated through its
ability to ﬁne-tune Ca2+ and Cl− currents across neuronal mem-
branes. Taken together, this led us to propose the possible antic-
onvulsant eﬀect of vitamin D. In the present study, the eﬀects of acute
and chronic administrations of vitamin D3 alone and in combination
with a sub-eﬀective dose of diazepam (as a typical anti-seizure drug)
were evaluated on pentylenetetrazole-induced seizure in mice.
2. Methods
2.1. Study design
In this interventional study, 120 Balb/c male mice, aged 2–3 months
and weighing 25–30 g, were housed and bred in the animal room of
Kashan University of Medical Sciences (Kashan, Iran). They were kept
in polypropylene cages (six animals per cage), at constant temperature
of 22 ± 2°C and humidity of 50%–55%, with an automatically con-
trolled 12:12 h light/dark cycle. All animals were fed regular mice chow
and water ad libitum (Jafari-Sabet et al., 2013). Animals were randomly
divided into the following groups (n=10 in each group).
1 Acute control group, which received only a single injection of 20 IU
of almond oil and paraﬃn mixture in half an hour before the be-
ginning of the PTZ infusion.
2 Chronic control group, which received the same injection once a day
for 14 days; PTZ-infusion began on the last day after the injection of
almond oil and paraﬃn mixture.
3 Three groups acutely received 2000, 4000 and 6000 IU/kg of vi-
tamin D3 in half an hour before the PTZ infusion.
4 Three groups chronically received 2000, 4000 and 6000 IU/kg of
vitamin D3 for 14 days prior to seizure induced by PTZ (Siegel et al.,
1984; Williamson et al., 2017).
5 Two groups received diazepam at concentrations of 0.1 and 1mg/
kg.
6 Two groups received combination of a sub-eﬀective dose of dia-
zepam and vitamin D3.
Vitamin D3 with concentrations of 2000, 4000 and 6000 IU was
prepared by mixing almond oil and paraﬃn. Diazepam (0.1 mg/kg and
1mg/kg) was also prepared. An intraperitoneal injection was per-
formed half an hour before the test in each group (Hamidi et al., 2014).
2.2. Seizure induction
Pentylenetetrazole (PTZ) was dissolved in the heparinized sterile
saline (0.9%) solution to prepare a fresh solution with a concentration
of 5mg/mL. Intravenous injection was performed in the lateral tail
vein. The infusion rate of administered PTZ was 0.3 mL/min. Before
testing, each mouse was weighed, placed in a clear acrylic plastic re-
strainer and its tail was immersed in a warm water bath (40–45 °C) for
60 s to dilate the tail veins. A dental carpule (27 G, Heraeus Kulzer,
Germany), which was connected by a polyethylene tube (No. 10) to a
50mL syringe preﬁlled with the heparinized PTZ solution, was used.
The needle was inserted into the mid length of the lateral tail vein. After
verifying the proper insertion by the appearance of blood in the infu-
sion tube, the needle was secured to the tail using a special tape. The
syringe was held in the adjustable motor driven infusion pump (TOP
Syringe Pump, Japan). During the infusion period, the animal could
move freely in the Plexiglas observation box with the aid of an attached
cannula. Each animal was observed throughout the infusion period. The
duration time between the start of infusion and onset of the seizure
stages was recorded in seconds and then converted to the threshold
convulsant dosage (i.e. mg of drug per kg of body weight). The
threshold concentration in mg/kg for the appearance of seizure signs
was calculated using the following formula (Kouchaki et al., 2016;
Mesdaghinia et al., 2010):
× × ×
×
Rate mL min Time s Concentration mg mL
Bodyweightofanimal
( / ) ( ) ( / ) 1000
60
2.3. Statistical analysis
Results are expressed as mean ± standard error of the mean (SEM).
Statistical analysis of the results was performed by one-way ANOVA for
seizure thresholds of each convulsion stage followed by the Tukey’s test
for multiple comparisons. P-value less than 0.05 was considered as
statistically signiﬁcant (Banafshe et al., 2007).
3. Results
3.1. Eﬀect of acute vitamin D3 administrations on seizure threshold
The mean clonic seizure threshold in the control group was
79 ± 2.76mg/kg, which showed no signiﬁcant diﬀerence compared to
the mean seizure threshold in the groups received 2000 IU/kg
(78 ± 2.65mg/kg), 4000 IU/kg (82 ± 2.16mg/kg) and 6000 IU/kg
(86 ± 3.76mg/kg) of vitamin D3 (Fig. 1). The mean threshold for tonic
seizures in the acute model for vehicle was 131.5 ± 4.3mg/kg and
these mean values in the groups received 2000, 4000 and 6000 IU/kg
vitamin D3 were 150.5 ± 8.2, 144.4 ± 6.2 and 138.2 ± 7.7mg/kg,
respectively. The diﬀerence among the groups was not statistically
signiﬁcant (Fig. 2).
3.2. Eﬀect of chronic vitamin D3 administrations on seizure threshold
The mean clonic seizure threshold in the chronic model was
78 ± 3.7mg/kg in the vehicle group and it was 85.1 ± 3.7mg/kg in
the group received 2000 IU/kg of vitamin D3, which was similar to the
vehicle group. The mean seizure threshold in the group received 4000
IU/kg of vitamin D3 was 104.3 ± 3.1mg/kg, which was signiﬁcantly
higher than that in the vehicle group (P < 0.001) and it was
99.5 ± 2.9mg/kg in the group received 6000 IU/kg of vitamin D3,
which was signiﬁcantly higher than that in the vehicle group
(P < 0.01) (Fig. 3). The mean tonic seizure threshold in the chronic
model for vehicle was 130 ± 3.7mg/kg; the mean values in the groups
received 2000, 4000, and 6000 IU of vitamin D3 were 173.5 ± 7mg/
kg, 179.9 ± 4mg/kg and 176.5 ± 4.3mg/kg, respectively, which
were signiﬁcantly higher in all the three groups than in the vehicle
group (P < 0.001) (Fig. 4).
3.3. Eﬀect of acute diazepam administrations on seizure threshold
To determine the minimum eﬀective and sub-eﬀective doses of
diazepam in PTZ-induced tonic-clonic seizures, this drug (1 and 0.1mg/
kg i.p.) was administered acutely half an hour before the PTZ infusion.
The mean clonic seizure threshold in the mice receiving diazepam
1mg/kg was 123.8 ± 8mg/kg, which was signiﬁcantly more than that
in the control group (P < 0.001). However, 0.1mg/kg of diazepam
had no signiﬁcant eﬀect on the seizure threshold (Fig. 5). The mean
tonic seizure threshold in the group received 1mg/kg diazepam was
212 ± 5.6mg/kg, which was signiﬁcantly higher than that in the
control group (P < 0.001). However, the mean tonic seizure threshold
in the group received 0.1mg/kg diazepam was 141 ± 6.5mg/kg
(Fig. 6).
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3.4. Eﬀect of a combination of diazepam and vitamin D3 on seizure
threshold
The mean clonic seizure threshold was 88 ± 2mg/kg in the group
received the combined dose of 0.1mg/kg diazepam and 6000 IU/kg
vitamin D3 in the acute form, which showed no signiﬁcant diﬀerence
compared to the vehicle group (77 ± 2mg/kg) (Fig. 7). The mean
tonic seizure threshold in the group received the combined dose of
0.1 mg/kg diazepam and 6000 IU/kg vitamin D3 in the acute form was
164 ± 8.4mg/kg, which was not signiﬁcantly diﬀerent from that of
the vehicle group (Fig. 8). Also, the mean clonic seizure threshold in the
group received the combined dose of 0.1mg/kg diazepam and 2000 IU/
kg vitamin D3 in the chronic form was 108 ± 6.3mg/kg, which was
signiﬁcantly higher compared to that of the vehicle group (77 ± 3mg/
kg) (P < 0.001) (Fig. 9). The mean tonic seizure threshold in the group
received the combined dose of 0.1mg/kg diazepam and 2000 IU/kg
vitamin D3 was 196mg/kg, which was signiﬁcantly higher compared to
that of the vehicle group (142mg/kg) (P < 0.001) (Fig. 10).
4. Discussion
In this study, the eﬀects of vitamin D3 administration in acute (half
an hour before seizure) and chronic (two weeks before induction of
seizure) regimens were examined on seizure threshold in mice and it
was found that administration of 2000, 4000 and 6000 IU/kg of vitamin
D half an hour before seizure induction had no eﬀect on clonic-tonic
seizure threshold. But, chronic administration of 4000 and 6000 IU/kg
of vitamin D signiﬁcantly increased the clonic seizure threshold and the
chronic administration of 2000, 4000, and 6000 IU/kg of vitamin D
signiﬁcantly increased the tonic seizure threshold. Concurrent admin-
istration of the ineﬀective dose of vitamin D (2000 IU/kg) and dia-
zepam resulted in a signiﬁcant increase in the seizure threshold. In fact,
vitamin D3 potentiates the eﬀect of diazepam in control of seizures.
Limited studies have been done to evaluate the eﬀects of vitamin D
on seizure. Role of 1,25-dihydroxyvitamin D (calcitriol) in chemically
induced seizure was investigated in mice. Calcitriol was subcutaneously
injected 40min before the induction of seizure. Finally, based on the
Racine's Scoring System, it was found that severity of seizure was lower
in mice treated with calcitriol (Kalueﬀ et al., 2005).
Results of this study showed that calcitriol had a direct anti-seizure
eﬀect. This study is generally consistent with our results but in our
study, acute injection of diﬀerent concentrations of vitamin D3 (2000,
4000 and 6000 IU/kg i.p.) did not increase the seizure threshold sig-
niﬁcantly. This diﬀerence is due to the administration of very high
Fig. 1. comparison of mean clonic seizure threshold doses between acute treatment with vitamin D3 (2000, 4000 and 6000 IU/kg i.p.) and vehicle. The results are
expressed as Mean ± S.E.M., n= 10 in all groups.
Fig. 2. comparison of mean tonic seizure threshold doses between acute treatment with vitamin D3 (2000, 4000 and 6000 IU/kg i.p.) and vehicle. The results are
expressed as Mean ± S.E.M., n= 10 in all groups.
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dosage (33 μg per mice is equal to 52,000 IU/kg) that it can explain the
reason of a single-dose eﬃcacy of calcitriol. Meanwhile, our data
showed that the chronic administration of lower dosage of vitamin D
(4000 IU/kg) signiﬁcantly increased the tonic and clonic seizure
threshold and this dosage is more practical and there is no concern
about side eﬀects and toxicity. Eﬃcacy of the chronic administration of
vitamin D (4000, and 6000 IU/kg) and ineﬀectiveness of acute dosing
suggest that slow genomic actions of vitamin D are possible antic-
onvulsive mechanisms but the anti-seizure eﬀect of an acute high do-
sage of calcitriol (52,000 IU/kg), which has been reported by Kalueﬀ
supports the rapid non-genomic action of calcitriol. In another pilot
study, vitamin D levels were measured in 25 epileptic patients and vi-
tamin D deﬁciency was normalized. The number of seizures was sig-
niﬁcantly reduced in the group received vitamin D supplement and it
was stated that the normalization of vitamin D levels had anti-seizure
eﬀects (Holló et al., 2012). The interaction between vitamin D and anti-
seizure medications such as lamotrigine and topiramate, in the max-
imum electro-shock test in mice has also been studied; it has been
shown that vitamin D not only has anti-seizure eﬀects, but also
strengthens the eﬀect of some anti-seizure medications (Kinga et al.,
2015; Borowicz et al., 2007).
A lack of a satisfactory response to pharmacotherapy of epilepsy is a
major neurological problem. One of the eﬀective approaches for
controlling pharmacoresistant seizures is represented by administration
of supplement and nutritional induction of ketogenesis. Ketogenic diets
are increasingly used all over the world, but this nutritional treatment
(see Giordano et al., 2014 for a review) also causes nutritional deﬁcits,
which hamper its eﬃcacy. One of the most remarkable nutritional
deﬁcits is vitamin and mineral deﬁciency (Marchiò et al., 2018) and it
has been suggested that a possible cause of the described worsening in
seizures occurring under the ketogenic diet could be a lack of adequate
supplementation with vitamin D (Lucchi et al., 2017).
The functions of vitamin D are mediated through the nuclear vi-
tamin D receptor (genomic eﬀects) and speciﬁc membrane receptors
(none-genomic eﬀects) (Cui et al., 2017). Compared to its genomic
actions, the non-genomic eﬀects of vitamin D in the brain have been
explored to a much less extent. Regulation of calcium channels and
activation of protein kinase C and mitogen-activated protein kinase
pathways are some of the non-genomic signal transduction events
triggered by calcitriol (Weng and Chung, 2016).
More recently, calcitriol has been reported to rapidly modulate sy-
naptic transmission in juvenile gonadotrophin-releasing hormone neu-
rons. Using the whole-cell patch clamp technique, it was shown that the
acute application of vitamin D decreased the inward currents induced
by the excitatory neurotransmitters NMDA and kainate, in a reversible
and action potential-independent manner (Bhattarai et al., 2017). Since
Fig. 3. The comparison of mean clonic seizure threshold doses between chronic treatment with vitamin D3 (2000, 4000 and 6000 IU/kg i.p.) and vehicle. The results
are expressed as Mean ± S.E.M., n= 10 in all groups. ** P < 0.01 and *** P < 0.001 versus vehicle.
Fig. 4. Comparison of mean tonic seizure threshold doses between chronic treatment with vitamin D3 (2000, 4000 and 6000 IU/kg i.p.) and vehicle. The results are
expressed as Mean ± S.E.M., n= 10 in all groups. *** P < 0.001 versus vehicle.
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Fig. 5. Comparison of the mean dose of the clonic seizure threshold in the animals receiving diazepam (1 and 0.1 mg/kg i.p.) with the control group. The results are
expressed as Mean ± S.E.M., n= 10 in all groups. ***P < 0.001 versus control group.
Fig. 6. Comparison of the mean dose of the tonic seizure threshold in the animals receiving diazepam (1 and 0.1 mg/kg i.p.) with the control group. The results are
expressed as Mean ± S.E.M., n= 10 in all groups. ***P < 0.001 versus control group.
Fig. 7. The mean clonic seizure threshold in the group received a combined dose of 0.1 mg/kg of diazepam and 6000 IU/kg of vitamin D3, acutely. The results are
expressed as Mean ± S.E.M., n= 10 in all groups.
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Fig. 8. The mean dose for tonic seizures threshold in the group received combined dose of 0.1 mg/kg of diazepam and 6000 IU/kg of vitamin D3, acutely. The results
are expressed as Mean ± S.E.M., n= 10 in all groups.
Fig. 9. The mean clonic seizure threshold in the group received vitamin D3 (2000 IU/kg), diazepam (0.1mg/kg) and mixture of vitamin D3 (2000 IU/kg) and
diazepam (0.1mg/kg). The results are expressed as Mean ± S.E.M., n=10 in all groups. ***P < 0.001 versus control group.
Fig. 10. The mean dose for tonic seizures threshold in the group received vitamin D3 (2000 IU/kg), diazepam (0.1mg/kg), and mixture of vitamin D3 (2000 IU/kg)
and diazepam (0.1 mg/kg). The results are expressed as Mean ± S.E.M., n= 10 in all groups. ** P < 0.01 and *** P < 0.001 versus vehicle.
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GABA-A receptors represent an important target for non-genomic action
of many neurosteroids such as vitamin D (Neveu et al., 1994) and
concerning the crucial role of the GABAergic system in epilepsy pa-
thogenesis, the speciﬁc GABA-inhibiting action of PTZ and potentation
of diazepam eﬀect with concurrent administration of vitamin D, it is
rational to suggest that vitamin D may act through modulation of
GABA-A receptors.
Vitamin D could mediate its neuronal eﬀects via modiﬁcation in
transcription of genes encoding a variety of neurotransmitters, en-
zymes, or cytokines in the nervous system. For example, it has been
shown that vitamin D reduces interleukin-6 activity recently reported to
be involved in epilepsy and exert pro-convulsant eﬀects in PTZ-induced
seizures in rats (Kalueﬀ et al., 2004). Vitamin D also inhibits the
synthesis of inducible nitric oxide synthase (iNOS), an enzyme induced
in CNS neurons during various insults or diseases. Nitric oxide plays an
important role in modulating seizure susceptibility (Garcion et al.,
1998). Also, blockade of NOS has been demonstrated to be the antic-
onvulsant mechanism of action of many compounds such as morphine,
dextrometrophan, and tramadol for PTZ-induced seizures in mice
(Mohseni et al., 2016). Vitamin D has also been reported to upregulate
γ-glutamyl transpeptidase activity and expression of the corresponding
gene in rat brain. Because γ-glutamyl transpeptidase is largely involved
in the glutathione cycle of the brain in crosstalk between astrocytes and
neurons, it has been proposed that vitamin D could control brain de-
toxiﬁcation processes. An increase in glutathione levels might be linked
to the anti-convulsant eﬀect of vitamin D (Garcion et al., 2002).
Another possible mechanism of vitamin D neuronal eﬀects is the
modulation of neuronal Ca2+ homeostasis. It was reported that vitamin
D down-regulates the L-type voltage-sensitive Ca2+ channel in hippo-
campal neurons, which has been correlated with a neuroprotective ef-
fect against excitotoxic insults (Brewer et al., 2001). Given that vitamin
D also plays an important role in digestive absorption of calcium, a
change in amount of extracellular and intracellular calcium can be
considered as a probable mechanism for changing the seizure threshold.
Vitamin D deﬁciency causes hypocalcemia that produces seizure due to
increased irritability of the neuron membrane. The anti-seizure activity
of vitamin D is probably resulted from its positive eﬀect on mineral
homeostasis and hormonal regulation; chronic treatment with anti-
seizure medications causes mineral homeostasis disorder in the pa-
tients, which increases seizure due to hypocalcemia and a decrease in
plasma levels of vitamin D (Teagarden et al., 2014).
5. Conclusions
According to the results of the present study, chronic administration
of vitamin D increases the PTZ-induced seizure threshold and the
combination of a sub-eﬀective dose of vitamin D3 and diazepam
(0.1 mg/kg), as a typical anticonvulsant drug, can signiﬁcantly increase
seizure threshold. In fact, vitamin D3 potentiates the anticonvulsant
eﬀect of diazepam and vitamin D as a supplement seems to be able to
reduce the required dose of anti-seizure medications. Also, due to vi-
tamin D deﬁciency results from the long-term use of most anti-seizure
medications, it is logical to administer vitamin D supplement in patients
with refractory epileptic seizures.
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